Literature DB >> 25638414

Accelerated vascular disease in systemic lupus erythematosus: role of macrophage.

Mohammed M Al Gadban1, Mohamed M Alwan1, Kent J Smith1, Samar M Hammad2.   

Abstract

Atherosclerosis is a chronic inflammatory condition that is considered a major cause of death worldwide. Striking phenomena of atherosclerosis associated with systemic lupus erythematosus (SLE) is its high incidence in young patients. Macrophages are heterogeneous cells that differentiate from hematopoietic progenitors and reside in different tissues to preserve tissue integrity. Macrophages scavenge modified lipids and play a major role in the development of atherosclerosis. When activated, macrophages secret inflammatory cytokines. This activation triggers apoptosis of cells in the vicinity of macrophages. As such, macrophages play a significant role in tissue remodeling including atherosclerotic plaque formation and rupture. In spite of studies carried on identifying the role of macrophages in atherosclerosis, this role has not been studied thoroughly in SLE-associated atherosclerosis. In this review, we address factors released by macrophages as well as extrinsic factors that may control macrophage behavior and their effect on accelerated development of atherosclerosis in SLE.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis;; Autoantibodies; Lipoprotein immune complexes;; Lupus;; Macrophage;; Sphingolipids;

Mesh:

Substances:

Year:  2015        PMID: 25638414      PMCID: PMC4410070          DOI: 10.1016/j.clim.2015.01.008

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  153 in total

1.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

Authors:  E F Borba; E Bonfá
Journal:  Lupus       Date:  1997       Impact factor: 2.911

2.  The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice.

Authors:  Avneesh K Singh; Jun-Qi Yang; Vrajesh V Parekh; Jie Wei; Chyung-Ru Wang; Sebastian Joyce; Ram R Singh; Luc Van Kaer
Journal:  Eur J Immunol       Date:  2005-04       Impact factor: 5.532

3.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes.

Authors:  T F Liu; B M Jones
Journal:  Cytokine       Date:  1998-02       Impact factor: 3.861

Review 5.  IL-17-producing T cells in lupus nephritis.

Authors:  S A Apostolidis; J C Crispín; G C Tsokos
Journal:  Lupus       Date:  2011-02       Impact factor: 2.911

6.  Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate.

Authors:  Douglas H Deutschman; Jeffrey S Carstens; Robert L Klepper; Wyatt S Smith; M Trevor Page; Thomas R Young; Lisa A Gleason; Nobuko Nakajima; Roger A Sabbadini
Journal:  Am Heart J       Date:  2003-07       Impact factor: 4.749

Review 7.  Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sahena Haque; Hoda Mirjafari; Ian N Bruce
Journal:  Curr Opin Lipidol       Date:  2008-08       Impact factor: 4.776

8.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

Review 9.  Adhesion molecules and atherosclerosis.

Authors:  Stefan Blankenberg; Sandrine Barbaux; Laurence Tiret
Journal:  Atherosclerosis       Date:  2003-10       Impact factor: 5.162

10.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  10 in total

1.  Blunting Autoantigen-induced FOXO3a Protein Phosphorylation and Degradation Is a Novel Pathway of Glucocorticoids for the Treatment of Systemic Lupus Erythematosus.

Authors:  Mudan Lu; Wei Xu; Bo Gao; Sidong Xiong
Journal:  J Biol Chem       Date:  2016-08-01       Impact factor: 5.157

2.  The Differential Influence of Immunological Process of Autoimmune Disease on Lipid Metabolism: A Study on RA and SLE.

Authors:  S Chandrashekara; Sachin Vithalrao Dhote; K R Anupama
Journal:  Indian J Clin Biochem       Date:  2017-11-13

Review 3.  Endothelial function and endothelial progenitor cells in systemic lupus erythematosus.

Authors:  Anselm Mak; Jerry Kok Yen Chan
Journal:  Nat Rev Rheumatol       Date:  2022-04-07       Impact factor: 20.543

Review 4.  Functional Lipids in Autoimmune Inflammatory Diseases.

Authors:  Michele Dei Cas; Gabriella Roda; Feng Li; Francesco Secundo
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

Review 5.  Macrophage Polarization and Plasticity in Systemic Lupus Erythematosus.

Authors:  Mariame Mohamed Ahamada; Yang Jia; Xiaochuan Wu
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

6.  Physical Activity and Systemic Lupus Erythematosus Among European Populations: A Two-Sample Mendelian Randomization Study.

Authors:  Shuo Huang; Fengyuan Tian; Xiaoxuan Yang; Sijia Fang; Yongsheng Fan; Jie Bao
Journal:  Front Genet       Date:  2022-02-08       Impact factor: 4.599

Review 7.  CD40 in coronary artery disease: a matter of macrophages?

Authors:  Matthijs F Jansen; Maurits R Hollander; Niels van Royen; Anton J Horrevoets; Esther Lutgens
Journal:  Basic Res Cardiol       Date:  2016-05-04       Impact factor: 17.165

8.  Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity.

Authors:  Samar M Hammad; Jasmyn R Hardin; Dulaney A Wilson; Waleed O Twal; Paul J Nietert; James C Oates
Journal:  PLoS One       Date:  2019-11-20       Impact factor: 3.240

Review 9.  Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus.

Authors:  Olivia C Harden; Samar M Hammad
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

10.  Plasma Sphingolipid Profile Associated With Subclinical Atherosclerosis and Clinical Disease Markers of Systemic Lupus Erythematosus: Potential Predictive Value.

Authors:  Samar M Hammad; Olivia C Harden; Dulaney A Wilson; Waleed O Twal; Paul J Nietert; Jim C Oates
Journal:  Front Immunol       Date:  2021-07-21       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.